Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Seeks Lenvima’s Label Expansion into Thymic Carcinoma
July 31, 2020
- Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
- Healios Starts Enrolling COVID-19 Patients in ARDS Cell Therapy Program
July 30, 2020
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Otsuka Files Japan NDA for Preventive Treatment of Migraines
July 30, 2020
- Generic APIs at Crossroads - 1: Sawai Quality Chief Says Current Biz Structure Hampers Manufacturing Repatriation
July 29, 2020
- Santen Bags Rights to Osmotica’s Droopy Eyelid Drug
July 29, 2020
- Eisai, DeNA Launch Smartphone App for Dementia Prevention
July 29, 2020
- Ibrance Now Available in Tablet Forms: Pfizer Japan
July 29, 2020
- Pfizer Japan Has Different Interpretation on Lyrica Patent Ruling
July 29, 2020
- Novartis Links Up with Ehime Pref., Ehime Univ. to Fuel Cardiovascular Disease Prevention
July 29, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- EU Panel Gives Thumbs-Up to Avastin Biosimilar
July 28, 2020
- Daiichi Sankyo, AstraZeneca to Collaborate for Another ADC
July 28, 2020
- Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid
July 28, 2020
- EU Panel Backs Kyowa Kirin’s Crysvita for Adult XLH
July 28, 2020
- StemRIM Bags 1.7 Billion Yen from Shionogi for Expanded Deal on Regeneration-Inducing Medicine
July 28, 2020
- Chugai, Biofourmis to Develop Digital Solution to Objectively Assess Endometriosis Pain
July 27, 2020
- Astellas Earns NIH Grant for Potential Opioid Use Disorder Med
July 27, 2020
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…